Contents
On this page
- The sustainability problem with bark extraction
- What elicited cell suspension cultures actually yield
- Semi-synthesis and total synthesis: the rest of the production picture
- Why cell technology is favoured despite the complexity
- Beyond Taxus: hairy roots, bioreactor engineering, and other plant-cell platforms
- Vincristine, artemisinin, and the limits of extending this comparison to other drugs
Academy · Research Data, Analytics & AI · Plant Cell Technology for Drugs
A Systematic Review and Meta-Analysis of Plant Cell Technology for Production of Natural-Based Drugs
Paclitaxel from tree bark requires felling old-growth yew trees at a yield of roughly 0.01% of dry weight; verified plant cell culture studies report yields of up to 38.2 mg/L of total taxanes under elicitation — real numbers that explain why cell technology, not extraction, is now the production method of choice.
Paclitaxel is the case study most often used to argue for plant cell culture over whole-plant extraction, because the sustainability problem with extraction is so stark and so well documented. The original source of paclitaxel, the bark of the Pacific yew (Taxus brevifolia), yields the compound at approximately 0.01% of dry bark weight, a ratio that also fluctuates seasonally — and a single treatment course (2.5-3 g of paclitaxel) has been estimated to require stripping the bark from roughly eight 60-year-old trees. That constraint is exactly why optimized Taxus cell suspension cultures, grown under controlled bioreactor conditions rather than harvested from mature trees, are described in the plant biotechnology literature as the current method of choice.
What you will learn
- The actual, verified yield figures for paclitaxel from Pacific yew bark extraction versus from elicited Taxus baccata cell suspension cultures.
- What 'elicitation' means in plant cell culture, and the specific elicitor combinations reported to multiply taxane yield in cell suspensions.
- Why total chemical synthesis and semi-synthesis from renewable needle-derived precursors are part of the production picture but do not replace cell culture or extraction outright.
What to unlearn
- “Plant cell culture techniques for paclitaxel report efficacy or yield figures in the 90-100% range.” The verified literature reports yields in mg/L of culture (for example, up to 38.2 mg/L total taxanes and 21 mg/L paclitaxel under combined elicitation in Taxus baccata suspensions), not a percentage efficacy figure — these are concentration yields from a bioreactor process, and no verifiable source reports a 90-100% 'efficacy' statistic for this comparison.
- “Cell culture and bark extraction yields can be directly compared as like-for-like percentages.” Bark yield is reported as roughly 0.01% of dry bark weight, while cell culture yield is reported in mg per litre of liquid culture — different units describing different production systems, so a direct side-by-side percentage comparison is not something the primary literature supports.
The sustainability problem with bark extraction
Perez-Matas E, Hanano A, Moyano E, Bonfill M, Cusido RM and Palazon J, writing in Frontiers in Plant Science in 2022, document the original extraction route for paclitaxel: the inner bark of Taxus brevifolia, yielding the compound at "in the order of 0.01%" of dry weight, a ratio that fluctuates seasonally1. Citing earlier work (Bedi et al., 1996), the authors note that a single treatment course requiring 2.5-3 g of paclitaxel has been estimated to need the bark of approximately eight 60-year-old yew trees1. The authors describe this extraction route as ecologically unsustainable at any meaningful treatment scale, which is the central motivation for alternative production methods.
What elicited cell suspension cultures actually yield
The same paper reports controlled experiments on Taxus baccata cell suspension cultures treated with elicitors — compounds added to the culture medium to trigger the plant cells' defensive secondary-metabolite production. In untreated control cultures, total taxane content never exceeded 5 mg/L1. Adding 1 mM coronatine (COR) raised total taxanes to 20 mg/L by day 24 (a 4.8-fold increase over control), with paclitaxel itself reaching 13 mg/L (an 11-fold increase over control)1. Combining coronatine with beta-cyclodextrins (CC treatment) pushed total taxanes to a peak of 38.2 mg/L by day 20 (a 9.3-fold increase over control), with paclitaxel reaching approximately 21 mg/L by the end of the culture period, roughly an 18-fold increase over control1.
These are concentration yields from a scalable, controlled bioreactor process rather than a one-time harvest from a decades-old tree, and the fold-increases show how much elicitation strategy matters: combined elicitors (CC) outperformed a single elicitor (COR alone) by roughly a further two-fold on paclitaxel yield in this dataset1.
Semi-synthesis and total synthesis: the rest of the production picture
The Perez-Matas et al. review also situates cell culture against the two other production routes in use. Semi-synthesis starts from precursor compounds — 10-deacetylbaccatin III and baccatin III — that can be extracted from yew needles, a renewable source that does not require felling the tree1. Total chemical synthesis of paclitaxel was achieved in 1994, but the authors describe it as commercially unfeasible at production scale1. Note that this verified source does not report comparable production figures for vincristine or vinblastine (other plant-derived oncology drugs sometimes discussed alongside paclitaxel); any claim about those compounds' cell-culture yields should be sourced separately rather than extrapolated from the paclitaxel data here.
Why cell technology is favoured despite the complexity
Put together, the verified figures explain the field's direction without needing an invented efficacy percentage: bark extraction is bounded by tree biology and an unsustainable harvest ratio, total synthesis is chemically proven but not economically viable, needle-derived semi-synthesis is renewable but still agriculturally dependent, and elicited cell suspension culture is the only route in this literature that is both scalable in a bioreactor and demonstrably responsive to process optimization — nearly a 20-fold increase in paclitaxel yield from a single elicitation strategy change, per the Perez-Matas et al. data1. That responsiveness to process control, more than any single yield number, is the strongest argument in the verified literature for describing optimized plant cell culture as the current method of choice.
Beyond Taxus: hairy roots, bioreactor engineering, and other plant-cell platforms
Elicited cell suspension culture is not the only plant-cell platform used for pharmaceutical production, and the wider literature situates the Taxus baccata results reported above against other systems in use for the same purpose. Hidalgo D, Sánchez R, Lalaleo L, Bonfill M, Corchete P and Palazon J, reviewing the biotechnological production of pharmaceuticals and biopharmaceuticals in plant cell and organ cultures in Current Medicinal Chemistry in 2018, describe both undifferentiated cell suspension cultures and differentiated organ cultures, hairy roots among them, as established production routes for plant secondary metabolites, citing paclitaxel from Taxus cell suspensions alongside ginsenosides and shikonin as examples where the approach has reached commercial or near-commercial scale.2 Wawrosch C and Zotchev SB's 2021 status-and-outlook review in Applied Microbiology and Biotechnology frames in vitro plant production technologies, elicitation included, as a maturing toolkit rather than a laboratory curiosity, while identifying the translation of a flask-scale elicitation result into a commercially viable bioreactor process as the main bottleneck most compounds still face.3
Hairy root cultures specifically are reported to carry a practical trade-off against undifferentiated suspension cultures. Urquiza-López and colleagues' 2025 PeerJ review of compounds produced in hairy root and transgenic hairy root cultures describes these Rhizobium rhizogenes-transformed root lines as more genetically and biochemically stable across repeated subculturing than suspension-cultured cells, while still being able to secrete target compounds into the medium and scale in bioreactors much as suspension cultures do.4 That stability cuts against the speed advantage the Taxus data showed above: a suspension culture can be elicited to a large fold-increase within weeks, as the coronatine and coronatine-plus-beta-cyclodextrin results demonstrate, but individual suspension lines are also reported to drift in productivity over successive subculturing in a way hairy root lines resist more reliably.4 On the engineering side, Motolinía-Alcántara and colleagues' 2021 review in Plants sets out the bioreactor variables that decide whether a shake-flask elicitation result survives scale-up at all — aeration strategy and the shear-stress tolerance of plant cells, oxygen transfer rate, and reactor geometry chief among them — which is precisely the translation step separating a published mg/L figure from an operating production process.5
Vincristine, artemisinin, and the limits of extending this comparison to other drugs
The caution flagged earlier in this article — that paclitaxel yield data should not be extrapolated to other plant-derived oncology drugs — is worth making concrete rather than leaving as a general warning. Almagro, Fernández-Pérez and Pedreño's 2015 review of indole alkaloid bioproduction from Catharanthus roseus in Molecules reports that vincristine and vinblastine, the plant's two best-known anticancer alkaloids, occur at genuinely low concentrations in the intact plant and are assembled from two precursors, catharanthine and vindoline, that are synthesized and stored in different leaf cell types — a compartmentalization problem that does not arise for the taxanes described above.6 The same review states plainly that C. roseus cell suspension cultures grown in bioreactors have shown very low alkaloid output, which has limited their industrial use for vincristine and vinblastine specifically; the cell-culture yield increases the review does report are for other indole alkaloids in the same pathway, such as ajmalicine, catharanthine, and vindoline (vindoline rising up to 117.6-fold under UV-B elicitation of cell suspensions, but only to roughly 0.06 mg/g dry weight).6 The largest reported vinblastine gains instead come from whole transgenic plants overexpressing the pathway regulators ORCA3 and G10H, which raised vinblastine roughly tenfold to about 0.27 mg/g dry weight — a genetic-engineering route applied to the intact plant, not a cell-culture yield comparable to the Taxus figures above.6
Artemisinin illustrates a third route again: engineering the plant's own biosynthetic pathway into a microbial host rather than growing plant cells at all. Paddon and colleagues, publishing in Nature in 2013, reconstituted the full artemisinic acid pathway from Artemisia annua in engineered Saccharomyces cerevisiae, reaching fermentation titres of roughly 25 g/L of artemisinic acid, then converted the purified acid to artemisinin through a four-step chemical process achieving about 40-45% overall yield.7 That is a materially different production architecture from the Taxus cell suspensions described earlier in this article — a plant pathway moved into a fast-growing microbial chassis rather than the plant's own cells kept in culture — and it is the reason artemisinin's production story and paclitaxel's cannot be treated as interchangeable evidence for how "plant cell technology" performs: one is cultured plant tissue, the other is a plant pathway expressed in yeast.
How a plant-cell-produced biologic actually reaches approval
Plant cell technology is used for more than small-molecule natural products; it has also produced an FDA-approved biologic, which gives a concrete regulatory precedent worth setting against the yield data above. Aviezer, Brill-Almon, Shaaltiel and colleagues reported in PLoS ONE in 2009 that a recombinant human glucocerebrosidase enzyme (prGCD) expressed in transformed carrot plant cells produced no drug-related adverse effects or anti-drug antibodies in monkeys or in six healthy human volunteers across a preclinical and Phase I investigation, and showed a longer half-life than imiglucerase, the existing mammalian-cell-produced enzyme replacement therapy.8 That Phase I result led directly to an FDA-reviewed Phase III trial, and FDA's own medical review of Biologics License Application 022458 documents the agency's May 2012 approval of the resulting product, taliglucerase alfa (marketed as Elelyso), for long-term enzyme replacement therapy in adults with Type 1 Gaucher disease.9
Elelyso remains one of the few plant-cell-expressed biologics to clear FDA approval, and De Martinis and colleagues' 2022 Frontiers in Plant Science editorial on engineering the "plant biofactory" situates it against a broader molecular farming landscape that includes plant-produced vaccine antigens and antibodies, while naming regulatory disharmony between jurisdictions, industry inertia, and a shortage of plant-specific manufacturing guidelines as the reasons more plant-cell-produced biologics have not followed it to market.10 Read against the yield and elicitation data earlier in this article, Elelyso's approval is the clearest evidence that plant cell technology's output is not confined to small-molecule natural products like paclitaxel — but it is also a reminder that a verified laboratory or bioreactor yield figure, on its own, is a long way from a regulatory-grade production process.
Take-home message
Take-home message
The real, verifiable comparison is not a 90-100% efficacy figure but a set of concentration yields: roughly 0.01% dry-weight bark extraction versus up to 38.2 mg/L total taxanes (about 21 mg/L paclitaxel) from elicited Taxus baccata cell suspension cultures, a gap large enough to explain the shift toward cell technology without exaggeration.
How to apply this to your work
How to apply this to your own work
- Cite yield figures in their original units. Report bark extraction as % dry weight and cell culture output as mg/L — do not convert either into an unsupported 'efficacy percentage' for comparison.
- Name the specific elicitor or elicitor combination. Yield claims for cell culture are elicitor-dependent; a bare 'cell culture yields more' claim is incomplete without specifying which elicitation strategy produced which number.
- Keep paclitaxel data separate from other plant-derived drugs unless independently sourced. Do not extend paclitaxel yield comparisons to vincristine, vinblastine, or other natural-product drugs without a separate verified source for each compound.
Common questions
No. The verified literature (Perez-Matas et al., 2022, Frontiers in Plant Science) reports yields in mg/L for cell culture and % dry weight for bark extraction — different units for different production systems — and does not report a combined 90-100% efficacy statistic for this comparison.
Combining coronatine with beta-cyclodextrins (the CC treatment) raised paclitaxel yield in Taxus baccata cell suspensions to approximately 21 mg/L, roughly an 18-fold increase over the untreated control's yield, as reported by Perez-Matas et al. (2022).
No. Almagro et al. (2015) report that Catharanthus roseus cell suspension cultures have shown very low alkaloid output industrially; the large reported gains for that plant's alkaloids come from elicited or transgenic whole plants (for example, roughly tenfold higher vinblastine from ORCA3/G10H-overexpressing transgenic plants), not from a bioreactor cell-culture yield comparable to the Taxus figures above.
Yes. Taliglucerase alfa (Elelyso), a recombinant glucocerebrosidase enzyme expressed in carrot plant cells for Gaucher disease, was approved by FDA in May 2012 after a Phase I investigation (Aviezer et al., 2009) found no drug-related adverse effects and a longer half-life than the existing mammalian-cell-produced enzyme.
References and sources
- Perez-Matas E, Hanano A, Moyano E, Bonfill M, Cusido RM, Palazon J. Insights into the control of taxane metabolism: molecular, cellular, and metabolic changes induced by elicitation in Taxus baccata cell suspensions. Frontiers in Plant Science. 2022;13:942433. read 10 October 2026. View on PubMed Central
- Hidalgo D, Sánchez R, Lalaleo L, Bonfill M, Corchete P, Palazon J. Biotechnological production of pharmaceuticals and biopharmaceuticals in plant cell and organ cultures. Current Medicinal Chemistry. 2018;25(30):3577-3596. read 10 October 2026. View source
- Wawrosch C, Zotchev SB. Production of bioactive plant secondary metabolites through in vitro technologies: status and outlook. Applied Microbiology and Biotechnology. 2021;105(18):6649-6668. read 10 October 2026. View on PubMed Central
- Urquiza-López et al. Compounds from medicinal plants produced in hairy root and transgenic hairy root cultures: a review. PeerJ. 2025;13:e19967. read 10 October 2026. View source
- Motolinía-Alcántara EA, Castillo-Araiza CO, Rodríguez-Monroy M, Román-Guerrero A, Cruz-Sosa F. Engineering considerations to produce bioactive compounds from plant cell suspension culture in bioreactors. Plants. 2021;10(12):2762. read 10 October 2026. View on PubMed Central
- Almagro L, Fernández-Pérez F, Pedreño MA. Indole alkaloids from Catharanthus roseus: bioproduction and their effect on human health. Molecules. 2015;20(2):2973-3000. read 10 October 2026. View on PubMed Central
- Paddon CJ, Westfall PJ, Pitera DJ, et al. High-level semi-synthetic production of the potent antimalarial artemisinin. Nature. 2013;496(7446):528-532. read 10 October 2026. View on Nature
- Aviezer D, Brill-Almon E, Shaaltiel Y, et al. A plant-derived recombinant human glucocerebrosidase enzyme: a preclinical and phase I investigation. PLoS ONE. 2009;4(3):e4792. read 10 October 2026. View on PubMed Central
- U.S. Food and Drug Administration. Medical Review(s), Biologics License Application 022458 (taliglucerase alfa / Elelyso), approved May 2012. read 10 October 2026. View on FDA.gov
- De Martinis D, Hitzeroth II, Matsuda R, Soto Pérez N, Benvenuto E. Editorial: Engineering the plant biofactory for the production of biologics and small-molecule medicines — Volume 2. Frontiers in Plant Science. 2022;13:942746. read 10 October 2026. View on PubMed Central
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 10). A Systematic Review and Meta-Analysis of Plant Cell Technology for Production of Natural-Based Drugs. Pubrica. https://pubrica.com/academy/systematic-review/a-systematic-review-and-meta-analysis-of-plant-cell-technology-for-production-of-natural-based-drugs-protocol-and-brief-outcome-paper-commentary/
Pubrica Academy. “A Systematic Review and Meta-Analysis of Plant Cell Technology for Production of Natural-Based Drugs.” Pubrica, 10 Oct. 2026, pubrica.com/academy/systematic-review/a-systematic-review-and-meta-analysis-of-plant-cell-technology-for-production-of-natural-based-drugs-protocol-and-brief-outcome-paper-commentary/.
Pubrica Academy (2026) A Systematic Review and Meta-Analysis of Plant Cell Technology for Production of Natural-Based Drugs. Pubrica. Available at: https://pubrica.com/academy/systematic-review/a-systematic-review-and-meta-analysis-of-plant-cell-technology-for-production-of-natural-based-drugs-protocol-and-brief-outcome-paper-commentary/ (Accessed: 15 October 2026).
Pubrica Academy. “A Systematic Review and Meta-Analysis of Plant Cell Technology for Production of Natural-Based Drugs.” Pubrica. October 10, 2026. https://pubrica.com/academy/systematic-review/a-systematic-review-and-meta-analysis-of-plant-cell-technology-for-production-of-natural-based-drugs-protocol-and-brief-outcome-paper-commentary/
Pubrica Academy, ‘A Systematic Review and Meta-Analysis of Plant Cell Technology for Production of Natural-Based Drugs’ (Pubrica, 10 October 2026) <https://pubrica.com/academy/systematic-review/a-systematic-review-and-meta-analysis-of-plant-cell-technology-for-production-of-natural-based-drugs-protocol-and-brief-outcome-paper-commentary/> accessed 15 October 2026.
Pubrica Academy. A Systematic Review and Meta-Analysis of Plant Cell Technology for Production of Natural-Based Drugs. [Internet]. Pubrica; 2026 Oct 10 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/systematic-review/a-systematic-review-and-meta-analysis-of-plant-cell-technology-for-production-of-natural-based-drugs-protocol-and-brief-outcome-paper-commentary/
Pubrica Academy, “A Systematic Review and Meta-Analysis of Plant Cell Technology for Production of Natural-Based Drugs,” Pubrica, Oct. 10, 2026. [Online]. Available: https://pubrica.com/academy/systematic-review/a-systematic-review-and-meta-analysis-of-plant-cell-technology-for-production-of-natural-based-drugs-protocol-and-brief-outcome-paper-commentary/
@misc{/la_plant_cell_technology_for_production_of_natural_based_drugs_2026,
author = {{Pubrica Academy}},
title = {A Systematic Review and Meta-Analysis of Plant Cell Technology for Production of Natural-Based Drugs},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/systematic-review/a-systematic-review-and-meta-analysis-of-plant-cell-technology-for-production-of-natural-based-drugs-protocol-and-brief-outcome-paper-commentary/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Checklist for citing plant cell technology yield data
Use this before quoting a plant cell culture yield or efficacy figure for a natural-product drug in a systematic review.
[ ] Confirmed the yield figure's exact unit (mg/L vs. % dry weight) before comparing routes [ ] Named the specific elicitor or elicitor combination behind any cell-culture yield claim [ ] Avoided converting concentration yields into an unsupported efficacy percentage [ ] Checked whether the source covers your specific compound (do not extrapolate across drugs) [ ] Cited the primary peer-reviewed source, not a secondary summary [ ] Confirmed whether a PRISMA-documented search/flow diagram is needed, or a narrative comparison is sufficient for the stated purpose
Pubrica AcademyWritten and maintained by the subject matter experts of Pubrica who do this work. Articles are revised when the standard underneath them moves, and each one carries the date it was last checked.
How Pubrica helps
Pubrica's plant biotechnology and systematic review writers trace every yield and efficacy figure in natural-product drug literature back to its primary source and reported unit, so no comparison is overstated.